Sumitomo Mitsui Trust Group Inc. Sells 39,987 Shares of Edwards Lifesciences Corporation $EW

Sumitomo Mitsui Trust Group Inc. reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 2.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,341,925 shares of the medical research company’s stock after selling 39,987 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Edwards Lifesciences were worth $114,399,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of EW. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences in the 3rd quarter valued at $25,000. True Wealth Design LLC increased its holdings in Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 164 shares during the last quarter. Dorato Capital Management bought a new stake in Edwards Lifesciences in the 4th quarter valued at $29,000. Finally, Rakuten Securities Inc. increased its holdings in Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of the stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,704,682.56. The trade was a 51.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 86,058 shares of company stock worth $7,118,636 in the last three months. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $78.02 on Tuesday. The company’s 50-day moving average price is $81.32 and its 200-day moving average price is $82.06. Edwards Lifesciences Corporation has a twelve month low of $68.63 and a twelve month high of $87.89. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The company has a market cap of $44.98 billion, a PE ratio of 42.63, a price-to-earnings-growth ratio of 2.03 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter last year, the firm earned $0.59 earnings per share. The business’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on EW. Piper Sandler reiterated an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $90.00 to $100.00 in a report on Thursday, December 18th. BTIG Research reiterated a “buy” rating and issued a $103.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, January 12th. Finally, Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, December 17th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.74.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.